+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Antibody Production Market by Product, Antibody Type, Production Process, Class, Purification Method, Application, End-User - Global Forecast to 2030- Product Image
Antibody Production Market by Product, Antibody Type, Production Process, Class, Purification Method, Application, End-User - Global Forecast to 2030- Product Image
Sale

Antibody Production Market by Product, Antibody Type, Production Process, Class, Purification Method, Application, End-User - Global Forecast to 2030

  • PDF Icon

    Report

  • 193 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 5888112
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The antibody production market is experiencing transformative growth, shaped by innovation in bioprocess technologies and changing global regulatory frameworks. Industry leaders facing supply chain complexities, evolving therapeutic needs, and tariff regulations must make informed strategic decisions to navigate this rapidly changing landscape.

Market Snapshot: Antibody Production Market Growth and Trends

The Antibody Production Market grew from USD 20.16 billion in 2024 to USD 22.62 billion in 2025. It is expected to continue growing at a CAGR of 12.45%, reaching USD 40.77 billion by 2030. Robust expansion is sustained by the increasing demand for antibodies in drug discovery, disease diagnostics, personalized medicine, and research applications. Upstream innovation, downstream process optimization, and adoption of advanced digital platforms are critical forces shaping competition. As R&D investments intensify, commercial opportunities for suppliers and manufacturers of reagents, bioreactors, analytics software, and modular systems increase significantly across regions.

Scope & Segmentation

  • Product Types: Consumables (buffers, reagents, chromatography resins, media), instruments (bioreactors, chromatography systems, filtration systems), and software.
  • Antibody Types: Monoclonal and polyclonal antibodies serve therapeutic, diagnostic, and research markets.
  • Production Process: Upstream and downstream processing, with innovation focused on cell line development and purification improvements.
  • Class: Includes IgA, IgD, IgE, IgG, and IgM, supporting diverse applications and markets.
  • Purification Method: Immobilized metal chelate chromatography, ion exchange chromatography, and size exclusion chromatography deliver flexibility for yield and purity demands.
  • Application: Diagnostics, research, and therapeutic uses such as autoimmune diseases, cancer therapy, infectious diseases, and neurological disorders.
  • End-User: Academic and research institutes, biotechnology companies, contract research organizations, and pharmaceutical companies, each with unique service and capacity needs.
  • Regions:
    • Americas: United States (including California, Texas, New York, Florida, Illinois, Pennsylvania, Ohio), Canada, Mexico, Brazil, Argentina.
    • Europe, Middle East & Africa: United Kingdom, Germany, France, Russia, Italy, Spain, United Arab Emirates, Saudi Arabia, South Africa, Denmark, Netherlands, Qatar, Finland, Sweden, Nigeria, Egypt, Turkey, Israel, Norway, Poland, Switzerland.
    • Asia-Pacific: China, India, Japan, Australia, South Korea, Indonesia, Thailand, Philippines, Malaysia, Singapore, Vietnam, Taiwan.
  • Technologies: Automation, real-time digital analytics, single-use bioreactor systems, and modular solutions designed for flexibility and compliance.
  • Competitive Landscape: Key players include AbbVie, Amgen, AstraZeneca, Biogen, Bristol-Myers Squibb, Cell Signaling Technology, Eppendorf, GE HealthCare, Genmab, GenScript, Gilead Sciences, INTEGRA Biosciences, Merck, Novartis, Novo Nordisk, Pall Corporation, Pfizer, ProteoGenix, Sanofi, Sartorius, Teva Pharmaceutical, The Antibody Company, Thermo Fisher Scientific, and Fibercell Systems.

Key Takeaways for Senior Decision-Makers

  • Technological progress in both upstream and downstream phases is optimizing process yield and production timelines for antibody manufacturing.
  • Strategic partnerships between equipment innovators and software vendors are accelerating the integration of data analytics and automation, streamlining bioprocessing workflows.
  • Geographic investments in manufacturing, especially across Asia-Pacific and localized hubs in the Americas and EMEA, are creating competitive advantages and strengthening supply chain resilience.
  • Regulatory authorities are actively updating process guidelines for digital record-keeping and continuous production, which influences supplier innovation and client compliance strategies.
  • Emerging biologics markets and biosimilars are shaping procurement priorities, driving the need for flexible manufacturing solutions tailored to autoimmune, oncology, infectious, and neurological conditions.
  • Growing importance is placed on operational agility, talent development in biotechnology and data sciences, and end-to-end digitalization to meet evolving market requirements.

Tariff Impact: Navigating Regulatory and Cost Pressures

The introduction of US tariff measures in 2025 has significantly altered supplier cost structures, especially for imported raw materials such as chromatography resins and filtration membranes. Organizations are responding with reshoring strategies, shifting toward domestic or nearshore partners, and increasing alliances across academia and industry to support localized production. These changes foster a more resilient supply base while mitigating exposure to geopolitical disruptions.

Methodology & Data Sources

Analysis is grounded in primary interviews with biotechnology executives, equipment suppliers, regulators, and academic stakeholders, complemented by secondary research from journals, industry reports, proprietary market data, and scenario-based sensitivity analysis. Rigorous cross-validation and expert reviews underpin the accuracy and reliability of all insights presented.

Why This Report Matters

  • Enables executives to pinpoint high-growth opportunities, technology trends, and regional expansion strategies—driving informed capital allocation and operational priorities.
  • Supports procurement, regulatory, and R&D teams with clear segmentation, tariff impact analysis, and competitive intelligence to strengthen sourcing, compliance, and portfolio management.

Conclusion

The antibody production market’s future lies in the strategic application of advanced technology, regionalized operations, and focused talent development. Firms equipped with these insights are positioned for sustainable growth and competitive advantage.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Rising prevalence of chronic diseases among consumers globally
5.1.1.2. Growing demand for targeted therapies and personalized medicines among consumers
5.1.1.3. Rapid modernization of healthcare infrastructure and increase in healthcare expenditure
5.1.2. Restraints
5.1.2.1. High costs associated with R&D for antibody production
5.1.3. Opportunities
5.1.3.1. Emerging applications of bispecific antibodies in cancer immunotherapy
5.1.3.2. Surge in research activities introducing novel plant-made monoclonal antibody
5.1.4. Challenges
5.1.4.1. Stringent regulatory frameworks for antibody production
5.2. Market Segmentation Analysis
5.2.1. Product : Significant applications of consumables in different stages of antibody production
5.2.2. Application : Expanding usage of antibody production in therapeutics due to the prevalence of chronic diseases
5.3. Porter’s Five Forces Analysis
5.3.1. Threat of New Entrants
5.3.2. Threat of Substitutes
5.3.3. Bargaining Power of Customers
5.3.4. Bargaining Power of Suppliers
5.3.5. Industry Rivalry
5.4. PESTLE Analysis
5.4.1. Political
5.4.2. Economic
5.4.3. Social
5.4.4. Technological
5.4.5. Legal
5.4.6. Environmental
6. Antibody Production Market, by Product
6.1. Introduction
6.2. Consumables
6.2.1. Buffers & Reagents
6.2.2. Chromatography Resins
6.2.3. Media
6.3. Instruments
6.3.1. Bioreactors
6.3.2. Chromatography Systems
6.3.3. Filtration Systems
6.4. Software
7. Antibody Production Market, by Antibody Type
7.1. Introduction
7.2. Monoclonal
7.3. Polyclonal
8. Antibody Production Market, by Production Process
8.1. Introduction
8.2. Downstream Processing
8.3. Upstream Processing
9. Antibody Production Market, by Class
9.1. Introduction
9.2. IgA
9.3. IgD
9.4. IgE
9.5. IgG
9.6. IgM
10. Antibody Production Market, by Purification Method
10.1. Introduction
10.2. Immobilized Metal Chelate Chromatography
10.3. Ion Exchange Chromatography
10.4. Size Exclusion Chromatography
11. Antibody Production Market, by Application
11.1. Introduction
11.2. Diagnostics
11.3. Research
11.4. Therapeutics
11.4.1. Autoimmune Diseases
11.4.2. Cancer Therapy
11.4.3. Infectious Diseases
11.4.4. Neurological Disorders
12. Antibody Production Market, by End-User
12.1. Introduction
12.2. Academic & Research Institutes
12.3. Biotechnology Companies
12.4. Contract Research Organizations
12.5. Pharmaceutical Companies
13. Americas Antibody Production Market
13.1. Introduction
13.2. Argentina
13.3. Brazil
13.4. Canada
13.5. Mexico
13.6. United States
14. Asia-Pacific Antibody Production Market
14.1. Introduction
14.2. Australia
14.3. China
14.4. India
14.5. Indonesia
14.6. Japan
14.7. Malaysia
14.8. Philippines
14.9. Singapore
14.10. South Korea
14.11. Taiwan
14.12. Thailand
14.13. Vietnam
15. Europe, Middle East & Africa Antibody Production Market
15.1. Introduction
15.2. Denmark
15.3. Egypt
15.4. Finland
15.5. France
15.6. Germany
15.7. Israel
15.8. Italy
15.9. Netherlands
15.10. Nigeria
15.11. Norway
15.12. Poland
15.13. Qatar
15.14. Russia
15.15. Saudi Arabia
15.16. South Africa
15.17. Spain
15.18. Sweden
15.19. Switzerland
15.20. Turkey
15.21. United Arab Emirates
15.22. United Kingdom
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Scenario Analysis
16.3.1. Sanofi invests EUR 40 million to elevate antibody production at Lyon site
16.3.2. AtomVie and Radiopharm Ventures team up to develop and manufacture monoclonal antibody 177Lu-BetaBart
16.3.3. GigaGen's contract with US BARDA accelerates recombinant polyclonal antibodies for BoNT and biothreats
16.4. Strategy Analysis & Recommendation
List of Figures
FIGURE 1. ANTIBODY PRODUCTION MARKET MULTI-CURRENCY
FIGURE 2. ANTIBODY PRODUCTION MARKET MULTI-LANGUAGE
FIGURE 3. ANTIBODY PRODUCTION MARKET RESEARCH PROCESS
FIGURE 4. ANTIBODY PRODUCTION MARKET SIZE, 2024 VS 2030
FIGURE 5. GLOBAL ANTIBODY PRODUCTION MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 6. GLOBAL ANTIBODY PRODUCTION MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL ANTIBODY PRODUCTION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 8. GLOBAL ANTIBODY PRODUCTION MARKET SIZE, BY PRODUCT, 2024 VS 2030 (%)
FIGURE 9. GLOBAL ANTIBODY PRODUCTION MARKET SIZE, BY PRODUCT, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 10. GLOBAL ANTIBODY PRODUCTION MARKET SIZE, BY ANTIBODY TYPE, 2024 VS 2030 (%)
FIGURE 11. GLOBAL ANTIBODY PRODUCTION MARKET SIZE, BY ANTIBODY TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 12. GLOBAL ANTIBODY PRODUCTION MARKET SIZE, BY PRODUCTION PROCESS, 2024 VS 2030 (%)
FIGURE 13. GLOBAL ANTIBODY PRODUCTION MARKET SIZE, BY PRODUCTION PROCESS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 14. GLOBAL ANTIBODY PRODUCTION MARKET SIZE, BY CLASS, 2024 VS 2030 (%)
FIGURE 15. GLOBAL ANTIBODY PRODUCTION MARKET SIZE, BY CLASS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 16. GLOBAL ANTIBODY PRODUCTION MARKET SIZE, BY PURIFICATION METHOD, 2024 VS 2030 (%)
FIGURE 17. GLOBAL ANTIBODY PRODUCTION MARKET SIZE, BY PURIFICATION METHOD, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 18. GLOBAL ANTIBODY PRODUCTION MARKET SIZE, BY APPLICATION, 2024 VS 2030 (%)
FIGURE 19. GLOBAL ANTIBODY PRODUCTION MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 20. GLOBAL ANTIBODY PRODUCTION MARKET SIZE, BY END-USER, 2024 VS 2030 (%)
FIGURE 21. GLOBAL ANTIBODY PRODUCTION MARKET SIZE, BY END-USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 22. AMERICAS ANTIBODY PRODUCTION MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 23. AMERICAS ANTIBODY PRODUCTION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 24. UNITED STATES ANTIBODY PRODUCTION MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 25. UNITED STATES ANTIBODY PRODUCTION MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 26. ASIA-PACIFIC ANTIBODY PRODUCTION MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 27. ASIA-PACIFIC ANTIBODY PRODUCTION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 28. EUROPE, MIDDLE EAST & AFRICA ANTIBODY PRODUCTION MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 29. EUROPE, MIDDLE EAST & AFRICA ANTIBODY PRODUCTION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 30. ANTIBODY PRODUCTION MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 31. ANTIBODY PRODUCTION MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. ANTIBODY PRODUCTION MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL ANTIBODY PRODUCTION MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL ANTIBODY PRODUCTION MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL ANTIBODY PRODUCTION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. ANTIBODY PRODUCTION MARKET DYNAMICS
TABLE 7. GLOBAL ANTIBODY PRODUCTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL ANTIBODY PRODUCTION MARKET SIZE, BY CONSUMABLES, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL ANTIBODY PRODUCTION MARKET SIZE, BY BUFFERS & REAGENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL ANTIBODY PRODUCTION MARKET SIZE, BY CHROMATOGRAPHY RESINS, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL ANTIBODY PRODUCTION MARKET SIZE, BY MEDIA, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL ANTIBODY PRODUCTION MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL ANTIBODY PRODUCTION MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL ANTIBODY PRODUCTION MARKET SIZE, BY BIOREACTORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL ANTIBODY PRODUCTION MARKET SIZE, BY CHROMATOGRAPHY SYSTEMS, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL ANTIBODY PRODUCTION MARKET SIZE, BY FILTRATION SYSTEMS, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL ANTIBODY PRODUCTION MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL ANTIBODY PRODUCTION MARKET SIZE, BY SOFTWARE, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL ANTIBODY PRODUCTION MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL ANTIBODY PRODUCTION MARKET SIZE, BY MONOCLONAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL ANTIBODY PRODUCTION MARKET SIZE, BY POLYCLONAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL ANTIBODY PRODUCTION MARKET SIZE, BY PRODUCTION PROCESS, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL ANTIBODY PRODUCTION MARKET SIZE, BY DOWNSTREAM PROCESSING, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL ANTIBODY PRODUCTION MARKET SIZE, BY UPSTREAM PROCESSING, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL ANTIBODY PRODUCTION MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL ANTIBODY PRODUCTION MARKET SIZE, BY IGA, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL ANTIBODY PRODUCTION MARKET SIZE, BY IGD, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL ANTIBODY PRODUCTION MARKET SIZE, BY IGE, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL ANTIBODY PRODUCTION MARKET SIZE, BY IGG, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL ANTIBODY PRODUCTION MARKET SIZE, BY IGM, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL ANTIBODY PRODUCTION MARKET SIZE, BY PURIFICATION METHOD, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL ANTIBODY PRODUCTION MARKET SIZE, BY IMMOBILIZED METAL CHELATE CHROMATOGRAPHY, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL ANTIBODY PRODUCTION MARKET SIZE, BY ION EXCHANGE CHROMATOGRAPHY, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL ANTIBODY PRODUCTION MARKET SIZE, BY SIZE EXCLUSION CHROMATOGRAPHY, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL ANTIBODY PRODUCTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL ANTIBODY PRODUCTION MARKET SIZE, BY DIAGNOSTICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL ANTIBODY PRODUCTION MARKET SIZE, BY RESEARCH, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL ANTIBODY PRODUCTION MARKET SIZE, BY THERAPEUTICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL ANTIBODY PRODUCTION MARKET SIZE, BY AUTOIMMUNE DISEASES, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL ANTIBODY PRODUCTION MARKET SIZE, BY CANCER THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL ANTIBODY PRODUCTION MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL ANTIBODY PRODUCTION MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL ANTIBODY PRODUCTION MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL ANTIBODY PRODUCTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL ANTIBODY PRODUCTION MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL ANTIBODY PRODUCTION MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL ANTIBODY PRODUCTION MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL ANTIBODY PRODUCTION MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 49. AMERICAS ANTIBODY PRODUCTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 50. AMERICAS ANTIBODY PRODUCTION MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
TABLE 51. AMERICAS ANTIBODY PRODUCTION MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
TABLE 52. AMERICAS ANTIBODY PRODUCTION MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
TABLE 53. AMERICAS ANTIBODY PRODUCTION MARKET SIZE, BY PRODUCTION PROCESS, 2018-2030 (USD MILLION)
TABLE 54. AMERICAS ANTIBODY PRODUCTION MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
TABLE 55. AMERICAS ANTIBODY PRODUCTION MARKET SIZE, BY PURIFICATION METHOD, 2018-2030 (USD MILLION)
TABLE 56. AMERICAS ANTIBODY PRODUCTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 57. AMERICAS ANTIBODY PRODUCTION MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 58. AMERICAS ANTIBODY PRODUCTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 59. AMERICAS ANTIBODY PRODUCTION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 60. ARGENTINA ANTIBODY PRODUCTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 61. ARGENTINA ANTIBODY PRODUCTION MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
TABLE 62. ARGENTINA ANTIBODY PRODUCTION MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
TABLE 63. ARGENTINA ANTIBODY PRODUCTION MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
TABLE 64. ARGENTINA ANTIBODY PRODUCTION MARKET SIZE, BY PRODUCTION PROCESS, 2018-2030 (USD MILLION)
TABLE 65. ARGENTINA ANTIBODY PRODUCTION MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
TABLE 66. ARGENTINA ANTIBODY PRODUCTION MARKET SIZE, BY PURIFICATION METHOD, 2018-2030 (USD MILLION)
TABLE 67. ARGENTINA ANTIBODY PRODUCTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 68. ARGENTINA ANTIBODY PRODUCTION MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 69. ARGENTINA ANTIBODY PRODUCTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 70. BRAZIL ANTIBODY PRODUCTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 71. BRAZIL ANTIBODY PRODUCTION MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
TABLE 72. BRAZIL ANTIBODY PRODUCTION MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
TABLE 73. BRAZIL ANTIBODY PRODUCTION MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
TABLE 74. BRAZIL ANTIBODY PRODUCTION MARKET SIZE, BY PRODUCTION PROCESS, 2018-2030 (USD MILLION)
TABLE 75. BRAZIL ANTIBODY PRODUCTION MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
TABLE 76. BRAZIL ANTIBODY PRODUCTION MARKET SIZE, BY PURIFICATION METHOD, 2018-2030 (USD MILLION)
TABLE 77. BRAZIL ANTIBODY PRODUCTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 78. BRAZIL ANTIBODY PRODUCTION MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 79. BRAZIL ANTIBODY PRODUCTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 80. CANADA ANTIBODY PRODUCTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 81. CANADA ANTIBODY PRODUCTION MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
TABLE 82. CANADA ANTIBODY PRODUCTION MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
TABLE 83. CANADA ANTIBODY PRODUCTION MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
TABLE 84. CANADA ANTIBODY PRODUCTION MARKET SIZE, BY PRODUCTION PROCESS, 2018-2030 (USD MILLION)
TABLE 85. CANADA ANTIBODY PRODUCTION MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
TABLE 86. CANADA ANTIBODY PRODUCTION MARKET SIZE, BY PURIFICATION METHOD, 2018-2030 (USD MILLION)
TABLE 87. CANADA ANTIBODY PRODUCTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 88. CANADA ANTIBODY PRODUCTION MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 89. CANADA ANTIBODY PRODUCTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 90. MEXICO ANTIBODY PRODUCTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 91. MEXICO ANTIBODY PRODUCTION MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
TABLE 92. MEXICO ANTIBODY PRODUCTION MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
TABLE 93. MEXICO ANTIBODY PRODUCTION MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
TABLE 94. MEXICO ANTIBODY PRODUCTION MARKET SIZE, BY PRODUCTION PROCESS, 2018-2030 (USD MILLION)
TABLE 95. MEXICO ANTIBODY PRODUCTION MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
TABLE 96. MEXICO ANTIBODY PRODUCTION MARKET SIZE, BY PURIFICATION METHOD, 2018-2030 (USD MILLION)
TABLE 97. MEXICO ANTIBODY PRODUCTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 98. MEXICO ANTIBODY PRODUCTION MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 99. MEXICO ANTIBODY PRODUCTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 100. UNITED STATES ANTIBODY PRODUCTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 101. UNITED STATES ANTIBODY PRODUCTION MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
TABLE 102. UNITED STATES ANTIBODY PRODUCTION MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
TABLE 103. UNITED STATES ANTIBODY PRODUCTION MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
TABLE 104. UNITED STATES ANTIBODY PRODUCTION MARKET SIZE, BY PRODUCTION PROCESS, 2018-2030 (USD MILLION)
TABLE 105. UNITED STATES ANTIBODY PRODUCTION MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
TABLE 106. UNITED STATES ANTIBODY PRODUCTION MARKET SIZE, BY PURIFICATION METHOD, 2018-2030 (USD MILLION)
TABLE 107. UNITED STATES ANTIBODY PRODUCTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 108. UNITED STATES ANTIBODY PRODUCTION MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 109. UNITED STATES ANTIBODY PRODUCTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 110. UNITED STATES ANTIBODY PRODUCTION MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 111. ASIA-PACIFIC ANTIBODY PRODUCTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 112. ASIA-PACIFIC ANTIBODY PRODUCTION MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
TABLE 113. ASIA-PACIFIC ANTIBODY PRODUCTION MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
TABLE 114. ASIA-PACIFIC ANTIBODY PRODUCTION MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
TABLE 115. ASIA-PACIFIC ANTIBODY PRODUCTION MARKET SIZE, BY PRODUCTION PROCESS, 2018-2030 (USD MILLION)
TABLE 116. ASIA-PACIFIC ANTIBODY PRODUCTION MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
TABLE 117. ASIA-PACIFIC ANTIBODY PRODUCTION MARKET SIZE, BY PURIFICATION METHOD, 2018-2030 (USD MILLION)
TABLE 118. ASIA-PACIFIC ANTIBODY PRODUCTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 119. ASIA-PACIFIC ANTIBODY PRODUCTION MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 120. ASIA-PACIFIC ANTIBODY PRODUCTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 121. ASIA-PACIFIC ANTIBODY PRODUCTION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 122. AUSTRALIA ANTIBODY PRODUCTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 123. AUSTRALIA ANTIBODY PRODUCTION MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
TABLE 124. AUSTRALIA ANTIBODY PRODUCTION MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
TABLE 125. AUSTRALIA ANTIBODY PRODUCTION MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
TABLE 126. AUSTRALIA ANTIBODY PRODUCTION MARKET SIZE, BY PRODUCTION PROCESS, 2018-2030 (USD MILLION)
TABLE 127. AUSTRALIA ANTIBODY PRODUCTION MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
TABLE 128. AUSTRALIA ANTIBODY PRODUCTION MARKET SIZE, BY PURIFICATION METHOD, 2018-2030 (USD MILLION)
TABLE 129. AUSTRALIA ANTIBODY PRODUCTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 130. AUSTRALIA ANTIBODY PRODUCTION MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 131. AUSTRALIA ANTIBODY PRODUCTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 132. CHINA ANTIBODY PRODUCTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 133. CHINA ANTIBODY PRODUCTION MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
TABLE 134. CHINA ANTIBODY PRODUCTION MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
TABLE 135. CHINA ANTIBODY PRODUCTION MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
TABLE 136. CHINA ANTIBODY PRODUCTION MARKET SIZE, BY PRODUCTION PROCESS, 2018-2030 (USD MILLION)
TABLE 137. CHINA ANTIBODY PRODUCTION MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
TABLE 138. CHINA ANTIBODY PRODUCTION MARKET SIZE, BY PURIFICATION METHOD, 2018-2030 (USD MILLION)
TABLE 139. CHINA ANTIBODY PRODUCTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 140. CHINA ANTIBODY PRODUCTION MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 141. CHINA ANTIBODY PRODUCTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 142. INDIA ANTIBODY PRODUCTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 143. INDIA ANTIBODY PRODUCTION MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
TABLE 144. INDIA ANTIBODY PRODUCTION MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
TABLE 145. INDIA ANTIBODY PRODUCTION MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
TABLE 146. INDIA ANTIBODY PRODUCTION MARKET SIZE, BY PRODUCTION PROCESS, 2018-2030 (USD MILLION)
TABLE 147. INDIA ANTIBODY PRODUCTION MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
TABLE 148. INDIA ANTIBODY PRODUCTION MARKET SIZE, BY PURIFICATION METHOD, 2018-2030 (USD MILLION)
TABLE 149. INDIA ANTIBODY PRODUCTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 150. INDIA ANTIBODY PRODUCTION MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 151. INDIA ANTIBODY PRODUCTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 152. INDONESIA ANTIBODY PRODUCTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 153. INDONESIA ANTIBODY PRODUCTION MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
TABLE 154. INDONESIA ANTIBODY PRODUCTION MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
TABLE 155. INDONESIA ANTIBODY PRODUCTION MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
TABLE 156. INDONESIA ANTIBODY PRODUCTION MARKET SIZE, BY PRODUCTION PROCESS, 2018-2030 (USD MILLION)
TABLE 157. INDONESIA ANTIBODY PRODUCTION MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
TABLE 158. INDONESIA ANTIBODY PRODUCTION MARKET SIZE, BY PURIFICATION METHOD, 2018-2030 (USD MILLION)
TABLE 159. INDONESIA ANTIBODY PRODUCTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 160. INDONESIA ANTIBODY PRODUCTION MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 161. INDONESIA ANTIBODY PRODUCTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 162. JAPAN ANTIBODY PRODUCTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 163. JAPAN ANTIBODY PRODUCTION MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
TABLE 164. JAPAN ANTIBODY PRODUCTION MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
TABLE 165. JAPAN ANTIBODY PRODUCTION MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
TABLE 166. JAPAN ANTIBODY PRODUCTION MARKET SIZE, BY PRODUCTION PROCESS, 2018-2030 (USD MILLION)
TABLE 167. JAPAN ANTIBODY PRODUCTION MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
TABLE 168. JAPAN ANTIBODY PRODUCTION MARKET SIZE, BY PURIFICATION METHOD, 2018-2030 (USD MILLION)
TABLE 169. JAPAN ANTIBODY PRODUCTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 170. JAPAN ANTIBODY PRODUCTION MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 171. JAPAN ANTIBODY PRODUCTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 172. MALAYSIA ANTIBODY PRODUCTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 173. MALAYSIA ANTIBODY PRODUCTION MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
TABLE 174. MALAYSIA ANTIBODY PRODUCTION MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
TABLE 175. MALAYSIA ANTIBODY PRODUCTION MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
TABLE 176. MALAYSIA ANTIBODY PRODUCTION MARKET SIZE, BY PRODUCTION PROCESS, 2018-2030 (USD MILLION)
TABLE 177. MALAYSIA ANTIBODY PRODUCTION MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
TABLE 178. MALAYSIA ANTIBODY PRODUCTION MARKET SIZE, BY PURIFICATION METHOD, 2018-2030 (USD MILLION)
TABLE 179. MALAYSIA ANTIBODY PRODUCTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 180. MALAYSIA ANTIBODY PRODUCTION MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 181. MALAYSIA ANTIBODY PRODUCTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 182. PHILIPPINES ANTIBODY PRODUCTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 183. PHILIPPINES ANTIBODY PRODUCTION MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
TABLE 184. PHILIPPINES ANTIBODY PRODUCTION MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
TABLE 185. PHILIPPINES ANTIBODY PRODUCTION MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
TABLE 186. PHILIPPINES ANTIBODY PRODUCTION MARKET SIZE, BY PRODUCTION PROCESS, 2018-2030 (USD MILLION)
TABLE 187. PHILIPPINES ANTIBODY PRODUCTION MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
TABLE 188. PHILIPPINES ANTIBODY PRODUCTION MARKET SIZE, BY PURIFICATION METHOD, 2018-2030 (USD MILLION)
TABLE 189. PHILIPPINES ANTIBODY PRODUCTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 190. PHILIPPINES ANTIBODY PRODUCTION MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 191. PHILIPPINES ANTIBODY PRODUCTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 192. SINGAPORE ANTIBODY PRODUCTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 193. SINGAPORE ANTIBODY PRODUCTION MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
TABLE 194. SINGAPORE ANTIBODY PRODUCTION MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
TABLE 195. SINGAPORE ANTIBODY PRODUCTION MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
TABLE 196. SINGAPORE ANTIBODY PRODUCTION MARKET SIZE, BY PRODUCTION PROCESS, 2018-2030 (USD MILLION)
TABLE 197. SINGAPORE ANTIBODY PRODUCTION MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
TABLE 198. SINGAPORE ANTIBODY PRODUCTION MARKET SIZE, BY PURIFICATION METHOD, 2018-2030 (USD MILLION)
TABLE 199. SINGAPORE ANTIBODY PRODUCTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 200. SINGAPORE ANTIBODY PRODUCTION MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 201. SINGAPORE ANTIBODY PRODUCTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 202. SOUTH KOREA ANTIBODY PRODUCTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 203. SOUTH KOREA ANTIBODY PRODUCTION MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
TABLE 204. SOUTH KOREA ANTIBODY PRODUCTION MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
TABLE 205. SOUTH KOREA ANTIBODY PRODUCTION MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
TABLE 206. SOUTH KOREA ANTIBODY PRODUCTION MARKET SIZE, BY PRODUCTION PROCESS, 2018-2030 (USD MILLION)
TABLE 207. SOUTH KOREA ANTIBODY PRODUCTION MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
TABLE 208. SOUTH KOREA ANTIBODY PRODUCTION MARKET SIZE, BY PURIFICATION METHOD, 2018-2030 (USD MILLION)
TABLE 209. SOUTH KOREA ANTIBODY PRODUCTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 210. SOUTH KOREA ANTIBODY PRODUCTION MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 211. SOUTH KOREA ANTIBODY PRODUCTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 212. TAIWAN ANTIBODY PRODUCTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 213. TAIWAN ANTIBODY PRODUCTION MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
TABLE 214. TAIWAN ANTIBODY PRODUCTION MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
TABLE 215. TAIWAN ANTIBODY PRODUCTION MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
TABLE 216. TAIWAN ANTIBODY PRODUCTION MARKET SIZE, BY PRODUCTION PROCESS, 2018-2030 (USD MILLION)
TABLE 217. TAIWAN ANTIBODY PRODUCTION MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
TABLE 218. TAIWAN ANTIBODY PRODUCTION MARKET SIZE, BY PURIFICATION METHOD, 2018-2030 (USD MILLION)
TABLE 219. TAIWAN ANTIBODY PRODUCTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 220. TAIWAN ANTIBODY PRODUCTION MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 221. TAIWAN ANTIBODY PRODUCTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 222. THAILAND ANTIBODY PRODUCTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 223. THAILAND ANTIBODY PRODUCTION MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
TABLE 224. THAILAND ANTIBODY PRODUCTION MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
TABLE 225. THAILAND ANTIBODY PRODUCTION MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
TABLE 226. THAILAND ANTIBODY PRODUCTION MARKET SIZE, BY PRODUCTION PROCESS, 2018-2030 (USD MILLION)
TABLE 227. THAILAND ANTIBODY PRODUCTION MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
TABLE 228. THAILAND ANTIBODY PRODUCTION MARKET SIZE, BY PURIFICATION METHOD, 2018-2030 (USD MILLION)
TABLE 229. THAILAND ANTIBODY PRODUCTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 230. THAILAND ANTIBODY PRODUCTION MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 231. THAILAND ANTIBODY PRODUCTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 232. VIETNAM ANTIBODY PRODUCTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 233. VIETNAM ANTIBODY PRODUCTION MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
TABLE 234. VIETNAM ANTIBODY PRODUCTION MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
TABLE 235. VIETNAM ANTIBODY PRODUCTION MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
TABLE 236. VIETNAM ANTIBODY PRODUCTION MARKET SIZE, BY PRODUCTION PROCESS, 2018-2030 (USD MILLION)
TABLE 237. VIETNAM ANTIBODY PRODUCTION MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
TABLE 238. VIETNAM ANTIBODY PRODUCTION MARKET SIZE, BY PURIFICATION METHOD, 2018-2030 (USD MILLION)
TABLE 239. VIETNAM ANTIBODY PRODUCTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 240. VIETNAM ANTIBODY PRODUCTION MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 241. VIETNAM ANTIBODY PRODUCTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 242. EUROPE, MIDDLE EAST & AFRICA ANTIBODY PRODUCTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 243. EUROPE, MIDDLE EAST & AFRICA ANTIBODY PRODUCTION MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
TABLE 244. EUROPE, MIDDLE EAST & AFRICA ANTIBODY PRODUCTION MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
TABLE 245. EUROPE, MIDDLE EAST & AFRICA ANTIBODY PRODUCTION MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
TABLE 246. EUROPE, MIDDLE EAST & AFRICA ANTIBODY PRODUCTION MARKET SIZE, BY PRODUCTION PROCESS, 2018-2030 (USD MILLION)
TABLE 247. EUROPE, MIDDLE EAST & AFRICA ANTIBODY PRODUCTION MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
TABLE 248. EUROPE, MIDDLE EAST & AFRICA ANTIBODY PRODUCTION MARKET SIZE, BY PURIFICATION METHOD, 2018-2030 (USD MILLION)
TABLE 249. EUROPE, MIDDLE EAST & AFRICA ANTIBODY PRODUCTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 250. EUROPE, MIDDLE EAST & AFRICA ANTIBODY PRODUCTION MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 251. EUROPE, MIDDLE EAST & AFRICA ANTIBODY PRODUCTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 252. EUROPE, MIDDLE EAST & AFRICA ANTIBODY PRODUCTION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 253. DENMARK ANTIBODY PRODUCTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 254. DENMARK ANTIBODY PRODUCTION MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
TABLE 255. DENMARK ANTIBODY PRODUCTION MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
TABLE 256. DENMARK ANTIBODY PRODUCTION MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
TABLE 257. DENMARK ANTIBODY PRODUCTION MARKET SIZE, BY PRODUCTION PROCESS, 2018-2030 (USD MILLION)
TABLE 258. DENMARK ANTIBODY PRODUCTION MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
TABLE 259. DENMARK ANTIBODY PRODUCTION MARKET SIZE, BY PURIFICATION METHOD, 2018-2030 (USD MILLION)
TABLE 260. DENMARK ANTIBODY PRODUCTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 261. DENMARK ANTIBODY PRODUCTION MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 262. DENMARK ANTIBODY PRODUCTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 263. EGYPT ANTIBODY PRODUCTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 264. EGYPT ANTIBODY PRODUCTION MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
TABLE 265. EGYPT ANTIBODY PRODUCTION MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
TABLE 266. EGYPT ANTIBODY PRODUCTION MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
TABLE 267. EGYPT ANTIBODY PRODUCTION MARKET SIZE, BY PRODUCTION PROCESS, 2018-2030 (USD MILLION)
TABLE 268. EGYPT ANTIBODY PRODUCTION MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
TABLE 269. EGYPT ANTIBODY PRODUCTION MARKET SIZE, BY PURIFICATION METHOD, 2018-2030 (USD MILLION)
TABLE 270. EGYPT ANTIBODY PRODUCTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 271. EGYPT ANTIBODY PRODUCTION MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 272. EGYPT ANTIBODY PRODUCTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 273. FINLAND ANTIBODY PRODUCTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 274. FINLAND ANTIBODY PRODUCTION MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
TABLE 275. FINLAND ANTIBODY PRODUCTION MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
TABLE 276. FINLAND ANTIBODY PRODUCTION MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
TABLE 277. FINLAND ANTIBODY PRODUCTION MARKET SIZE, BY PRODUCTION PROCESS, 2018-2030 (USD MILLION)
TABLE 278. FINLAND ANTIBODY PRODUCTION MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
TABLE 279. FINLAND ANTIBODY PRODUCTION MARKET SIZE, BY PURIFICATION METHOD, 2018-2030 (USD MILLION)
TABLE 280. FINLAND ANTIBODY PRODUCTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 281. FINLAND ANTIBODY PRODUCTION MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 282. FINLAND ANTIBODY PRODUCTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 283. FRANCE ANTIBODY PRODUCTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 284. FRANCE ANTIBODY PRODUCTION MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
TABLE 285. FRANCE ANTIBODY PRODUCTION MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
TABLE 286. FRANCE ANTIBODY PRODUCTION MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
TABLE 287. FRANCE ANTIBODY PRODUCTION MARKET SIZE, BY PRODUCTION PROCESS, 2018-2030 (USD MILLION)
TABLE 288. FRANCE ANTIBODY PRODUCTION MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
TABLE 289. FRANCE ANTIBODY PRODUCTION MARKET SIZE, BY PURIFICATION METHOD, 2018-2030 (USD MILLION)
TABLE 290. FRANCE ANTIBODY PRODUCTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 291. FRANCE ANTIBODY PRODUCTION MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 292. FRANCE ANTIBODY PRODUCTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 293. GERMANY ANTIBODY PRODUCTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 294. GERMANY ANTIBODY PRODUCTION MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
TABLE 295. GERMANY ANTIBODY PRODUCTION MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
TABLE 296. GERMANY ANTIBODY PRODUCTION MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
TABLE 297. GERMANY ANTIBODY PRODUCTION MARKET SIZE, BY PRODUCTION PROCESS, 2018-2030 (USD MILLION)
TABLE 298. GERMANY ANTIBODY PRODUCTION MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
TABLE 299. GERMANY ANTIBODY PRODUCTION MARKET SIZE, BY PURIFICATION METHOD, 2018-2030 (USD MILLION)
TABLE 300. GERMANY ANTIBODY PRODUCTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 301. GERMANY ANTIBODY PRODUCTION MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 302. GERMANY ANTIBODY PRODUCTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 303. ISRAEL ANTIBODY PRODUCTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 304. ISRAEL ANTIBODY PRODUCTION MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
TABLE 305. ISRAEL ANTIBODY PRODUCTION MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
TABLE 306. ISRAEL ANTIBODY PRODUCTION MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
TABLE 307. ISRAEL ANTIBODY PRODUCTION MARKET SIZE, BY PRODUCTION PROCESS, 2018-2030 (USD MILLION)
TABLE 308. ISRAEL ANTIBODY PRODUCTION MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
TABLE 309. ISRAEL ANTIBODY PRODUCTION MARKET SIZE, BY PURIFICATION METHOD, 2018-2030 (USD MILLION)
TABLE 310. ISRAEL ANTIBODY PRODUCTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 311. ISRAEL ANTIBODY PRODUCTION MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 312. ISRAEL ANTIBODY PRODUCTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 313. ITALY ANTIBODY PRODUCTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 314. ITALY ANTIBODY PRODUCTION MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
TABLE 315. ITALY ANTIBODY PRODUCTION MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
TABLE 316. ITALY ANTIBODY PRODUCTION MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
TABLE 317. ITALY ANTIBODY PRODUCTION MARKET SIZE, BY PRODUCTION PROCESS, 2018-2030 (USD MILLION)
TABLE 318. ITALY ANTIBODY PRODUCTION MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
TABLE 319. ITALY ANTIBODY PRODUCTION MARKET SIZE, BY PURIFICATION METHOD, 2018-2030 (USD MILLION)
TABLE 320. ITALY ANTIBODY PRODUCTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 321. ITALY ANTIBODY PRODUCTION MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 322. ITALY ANTIBODY PRODUCTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 323. NETHERLANDS ANTIBODY PRODUCTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 324. NETHERLANDS ANTIBODY PRODUCTION MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
TABLE 325. NETHERLANDS ANTIBODY PRODUCTION MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
TABLE 326. NETHERLANDS ANTIBODY PRODUCTION MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
TABLE 327. NETHERLANDS ANTIBODY PRODUCTION MARKET SIZE, BY PRODUCTION PROCESS, 2018-2030 (USD MILLION)
TABLE 328. NETHERLANDS ANTIBODY PRODUCTION MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
TABLE 329. NETHERLANDS ANTIBODY PRODUCTION MARKET SIZE, BY PURIFICATION METHOD, 2018-2030 (USD MILLION)
TABLE 330. NETHERLANDS ANTIBODY PRODUCTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 331. NETHERLANDS ANTIBODY PRODUCTION MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 332. NETHERLANDS ANTIBODY PRODUCTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 333. NIGERIA ANTIBODY PRODUCTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 334. NIGERIA ANTIBODY PRODUCTION MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
TABLE 335. NIGERIA ANTIBODY PRODUCTION MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
TABLE 336. NIGERIA ANTIBODY PRODUCTION MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
TABLE 337. NIGERIA ANTIBODY PRODUCTION MARKET SIZE, BY PRODUCTION PROCESS, 2018-2030 (USD MILLION)
TABLE 338. NIGERIA ANTIBODY PRODUCTION MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
TABLE 339. NIGERIA ANTIBODY PRODUCTION MARKET SIZE, BY PURIFICATION METHOD, 2018-2030 (USD MILLION)
TABLE 340. NIGERIA ANTIBODY PRODUCTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 341. NIGERIA ANTIBODY PRODUCTION MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 342. NIGERIA ANTIBODY PRODUCTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 343. NORWAY ANTIBODY PRODUCTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 344. NORWAY ANTIBODY PRODUCTION MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
TABLE 345. NORWAY ANTIBODY PRODUCTION MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
TABLE 346. NORWAY ANTIBODY PRODUCTION MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
TABLE 347. NORWAY ANTIBODY PRODUCTION MARKET SIZE, BY PRODUCTION PROCESS, 2018-2030 (USD MILLION)
TABLE 348. NORWAY ANTIBODY PRODUCTION MARKET SIZE, BY CLASS, 2018

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Antibody Production market report include:
  • AbbVie Inc.
  • Amgen Inc.
  • AstraZeneca PLC
  • Biogen Inc.
  • Bristol-Myers Squibb Company
  • Cell Signaling Technology, Inc.
  • Eppendorf AG
  • F. Hoffmann-La Roche Ltd.
  • Fibercell Systems Inc
  • GE HealthCare Technologies Inc.
  • Genmab A/S
  • GenScript Biotech Corporation
  • Gilead Sciences, Inc.
  • INTEGRA Biosciences AG
  • Merck KGaA
  • Novartis AG
  • Novo Nordisk A/S
  • Pall Corporation
  • Pfizer Inc.
  • ProteoGenix
  • Sanofi S.A.
  • Sartorius AG
  • Teva Pharmaceutical Industries Ltd.
  • The Antibody Company
  • Thermo Fisher Scientific Inc.

Table Information

Report AttributeDetails
No. of Pages193
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 22.62 Billion
Forecasted Market Value ( USD ) by 2030 $ 40.77 Billion
Compound Annual Growth Rate12.4%
Regions CoveredGlobal
No. of Companies Mentioned26

Related Topics

Related Reports

Mammalian Polyclonal IgG Antibody Market by Animal Source, Application, Purification Method, End User, Formulation, Distribution Channel - Global Forecast to 2030 - Product Image

Mammalian Polyclonal IgG Antibody Market by Animal Source, Application, Purification Method, End User, Formulation, Distribution Channel - Global Forecast to 2030

  • Report
  • 197 Pages
  • Global
From
Custom Polyclonal Antibody Production Service Market by Product Type, Application, End User, Purification Technique, Technology - Global Forecast to 2030 - Product Image

Custom Polyclonal Antibody Production Service Market by Product Type, Application, End User, Purification Technique, Technology - Global Forecast to 2030

  • Report
  • 190 Pages
  • Global
From
Bispecific Antibody Therapeutics Contract Manufacturing - Global Strategic Business Report - Product Image

Bispecific Antibody Therapeutics Contract Manufacturing - Global Strategic Business Report

  • Report
  • 382 Pages
  • Global
From
Polyclonal Antibodies - Global Strategic Business Report - Product Image

Polyclonal Antibodies - Global Strategic Business Report

  • Report
  • 63 Pages
  • Global
From
Cancer Monoclonal Antibodies - Market Insights, Competitive Landscape, and Market Forecast - 2030 - Product Image

Cancer Monoclonal Antibodies - Market Insights, Competitive Landscape, and Market Forecast - 2030

  • Report
  • 150 Pages
  • Global
From

About the Antibody Production Market

The Antibody Production market is a segment of the biopharmaceutical industry that focuses on the production of antibodies for therapeutic and diagnostic purposes. Antibodies are proteins that are produced by the immune system to recognize and bind to specific antigens, such as bacteria and viruses. Antibody production involves the use of recombinant DNA technology to produce large quantities of antibodies for use in research, diagnostics, and therapeutics. The market is driven by the increasing demand for biopharmaceuticals, as well as the development of new technologies and techniques for producing antibodies. The Antibody Production market is highly competitive, with a number of companies offering a range of products and services. Some of the major players in the market include AbbVie, Amgen, AstraZeneca, Biogen, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Merck, Novartis, Pfizer, and Roche. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.